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Elevated plasma abscisic acid is 
associated with asymptomatic 
falciparum malaria and with IgG-/
caspase-1-dependent immunity in 
Plasmodium yoelii-infected mice
Elizabeth K. K. Glennon  1,7, Dewi Megawati1,8, Brandi K. Torrevillas1,8, Isaac Ssewanyana2,3, 
Liusheng Huang4, Fran Aweeka4, Bryan Greenhouse5, L. Garry Adams6 & Shirley Luckhart1,8
Abscisic acid (ABA) is an ancient stress hormone and is detectable in a wide variety of organisms where 
it regulates innate immunity and inflammation. Previously, we showed that oral supplementation with 
ABA decreased parasitemia in a mouse model of malaria, decreased liver and spleen pathology and 
reduced parasite transmission to mosquitoes. Here, we report that higher circulating ABA levels were 
associated with a reduced risk of symptomatic malaria in a cohort of Plasmodium falciparum-infected 
Ugandan children. To understand possible mechanisms of ABA protection in malaria, we returned to 
our mouse model to show that ABA effects on Plasmodium yoelii 17XNL infection were accompanied 
by minimal effects on complete blood count and blood chemistry analytes, suggesting a benefit to 
host health. In addition, orally delivered ABA induced patterns of gene expression in mouse liver 
and spleen that suggested enhancement of host anti-parasite defenses. To test these inferences, we 
utilized passive immunization and knockout mice to demonstrate that ABA supplementation increases 
circulating levels of protective, parasite-specific IgG and requires caspase-1 to reduce parasitemia. 
Collectively, ABA induces host responses that ameliorate infection and disease in an animal model and 
suggest that further studies of ABA in the context of human malaria are warranted.
Little is currently known about the effects of abscisic acid (ABA) on innate and adaptive immunity to infection 
and less yet about the mechanisms underlying these effects. Treatment with ABA has been shown to activate 
granulocytes, monocytes, and microglial cells in vitro, increasing phagocytosis, production of reactive oxygen 
species (ROS) and nitric oxide (NO), enhancing nuclear factor (NF)-κB nuclear translocation and release of 
monocyte chemotactic protein (MCP-1) and tumor necrosis factor α (TNFα)1–4. Interestingly, ABA decreased 
TNFα expression in white adipose tissue in a model of inflammatory bowel disease and reduced MCP-1 expres-
sion and leukocyte infiltration in the lungs of mice with influenza5,6. Taken together, these data suggest that the 
effects of ABA on inflammatory signaling are organ- and context-dependent.
The generalized immune response to Plasmodium infection is characterized by a switch from an early 
pro-inflammatory response to an anti-inflammatory response near peak parasitemia, followed by antibody- 
mediated parasite clearance. During P. yoelii infection, IgM antibodies are transiently produced, with protective 
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IgG antibodies (e.g., IgG1, IgG2b) becoming predominant later in infection7–9. The innate immune response to 
Plasmodium infection includes clearance of infected red blood cells (iRBCs) by macrophages and dendritic cells 
in the liver and spleen as well as pro-inflammatory cytokine production following inflammasome activation and 
signaling through Toll-like receptors and NF-κB10. Detection of hemozoin and parasite genomic DNA within the 
hepatocyte phagolysosome can activate the inflammasome leading to increased production of interleukin (IL)-18 
and IL-1β, which are toxic to the parasite11. Macrophages secrete IL-1β, interferon γ (IFNγ), and TNFα, which 
enhance intrahepatic killing of parasites and induce natural killer (NK) cell cytotoxicity12–14. TNFα is necessary 
for IFNγ production by NK cells and is associated with resolution of fever during malaria15.
Reciprocal induction of pro-inflammatory cytokine secretion in positive feedback loops can lead to an over-
active immune response and immunopathology in malaria16. In this context, peroxisome proliferator-activated 
receptor gamma (PPARγ) is an important regulator of immunity and inflammation. PPARγ agonists have 
been proposed as malaria therapeutics and can increase CD36-mediated phagocytosis of iRBCs while reduc-
ing malaria-induced TNFα secretion17–19. ABA can enhance PPARγ levels, and ABA-associated reductions in 
inflammation were observed to be PPARγ-dependent in inflammatory bowel disease and influenza5,20. Similarly, 
in lipopolysaccharide (LPS)-challenged mice, ABA decreased splenic expression of il6, tnfα, and ifnγ in a 
PPARγ-dependent manner21. We previously demonstrated that ABA supplementation in P. yoelii 17XNL-infected 
CD-1 mice reduced parasitemia while increasing pparγ expression and decreasing NO synthase (nos) expression 
in both liver and spleen22.
Here, we report that Ugandan children with asymptomatic falciparum malaria (no fever) had higher circu-
lating plasma ABA levels than did children with symptomatic disease (fever at presentation). Based on these 
observations, we returned to our genetically tractable model to investigate possible mechanisms of ABA action 
during Plasmodium infection. We show that orally delivered ABA did not alter complete blood cell count and 
clinical chemistry analytes in uninfected mice and improved some of these parameters during P. yoelii 17XNL 
infection. Further, the beneficial effects of elevated plasma ABA on P. yoelii 17XNL infection were dependent on 
caspase-1 and on increased production of IgG, suggesting that elevated plasma ABA may be clinically relevant 
and protective in falciparum malaria.
Results
Reduced risk of symptomatic malaria in P. falciparum infected children was associated with 
higher plasma ABA levels. We quantified ABA levels as previously described22 in 122 plasma samples from 
P. falciparum infected children in Uganda. Children were selected from the Nagongera and Kanungu surveillance 
cohorts of the East Africa International Center of Excellence for Malaria Research (ICEMR). These cohorts were 
established in 2011 for health monitoring, including regular visits every 30–90 days during which blood smears 
and plasma samples were obtained regardless of symptoms23. Plasma samples from parasitemic children ages 2–4 
and 7–9 years were selected randomly with stratification by age and parasite density.
Children with higher plasma ABA levels had asymptomatic infections, not presenting with fever (Fig. 1). 
These patterns remained evident when samples were stratified by age group (Supplementary Fig. 1), however 
ABA levels did not correlate with parasitemia (Supplementary Fig. 1). Importantly, plasma levels in children with 
falciparum malaria were in the same range (<1–100 nM) as detected previously in our mouse model22.
ABA supplementation reduced disease and improved blood urea nitrogen levels in P. yoelii 
17XNL-infected C57BL/6 mice. Our previous studies utilized outbred mice (CD-1 strain) to examine the 
effects of ABA on P. yoelii 17XNL parasitemia, pathology and transmission22. Here, we established a model for 
mechanistic studies with C57BL/6 mice. As in our studies with CD-1 mice, 6–8 week old C57BL/6 mice received 
Figure 1. Asymptomatic falciparum malaria in children was associated with higher plasma ABA levels. ABA 
levels in plasma samples from children, ages 2–9, with detectable P. falciparum parasitemia. Only children 
without fever (asymptomatic malaria) had plasma ABA concentrations in excess of 20 nM. Each dot represents 
one individual (n = 122; 39 with fever, 83 without fever). Data were analyzed by Welch two sample t-test 
(p = 0.003).
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water containing 2.56 mM ABA for three days prior to and throughout the course of infection with P. yoelii 
17XNL. In four separate cohorts of C57BL/6 mice, we affirmed that ABA supplementation significantly reduced 
parasitemia (Fig. 2, Supplementary Fig. 2) compared to unsupplemented mice.
At day 9 post-infection (PI), all infected mice exhibited hepatomegaly and splenomegaly typical of malaria (not 
shown)24. Livers of ABA supplemented mice, however, weighed significantly less than those of unsupplemented 
mice (Fig. 3A), and there was a trend towards reduced spleen weight with ABA supplementation (Fig. 3B). This was 
Figure 2. ABA supplementation significantly reduced parasitemia in C57BL/6 mice infected with P. yoelii 
17XNL. Daily parasitemias of mice with and without oral ABA supplementation. Four replicates were 
conducted with 3–5 mice per treatment in each replicate. Mouse cohorts were sacrificed for analyses on days 9, 
11 and 13, reducing animal numbers after these days. Data were analyzed by unpaired t-test.
Figure 3. ABA supplemented mice have reduced hepatosplenomegaly. Weights of whole liver (A) and whole 
spleen (B) at day 9 PI from P. yoelii 17XNL-infected mice with and without ABA supplementation. Each dot 
represents one mouse sacrificed from a single cohort from the data represented in Fig. 2. Data were analyzed by 
unpaired t-test.
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consistent with our previous findings that ABA reduced inflammatory pathology, including microabscesses and 
leukocyte infiltration in the liver and hyperplasia in the spleen during P. yoelii 17XNL infection22.
Mouse plasma was analyzed for ABA concentration by liquid chromatography-tandem mass spectrometry 
(LC-MS/MS, University of California San Francisco Drug Research Unit) and for a variety of analytical markers 
of overall health (University of California Davis Comparative Pathology Lab). Plasma ABA levels were elevated by 
daily ad libitum supplementation in the presence and absence of infection (day 10 PI), with variation likely result-
ing from patterns and timing of water consumption (Fig. 4). Relative to previous observations22, supplemented 
infected C57BL/6 mice exhibited notably higher levels of plasma ABA than did supplemented CD-1 mice at a 
similar stage of infection, perhaps due to differences in mouse strain, enhanced sensitivity of LC-MS/MS versus 
ELISA or both.
In the presence and absence of infection, ABA supplementation had no effect on levels of plasma albumin, 
creatine, phosphorus, bilirubin, or total protein (Supplementary Table S1). Infected mice had significantly lower 
blood urea nitrogen (BUN) levels than uninfected mice (Fig. 5A). ABA supplementation had no effect on BUN 
levels in uninfected mice but, in the context of infection, ABA-treated mice had plasma BUN levels that were not 
significantly different from those in uninfected mice (Fig. 5A). Although increased BUN levels have been associ-
ated with kidney damage, abnormally low levels can also be indicative of impaired liver function25–27, suggesting 
that the effects of ABA extend beyond resolution of liver histopathology to improved function.
ABA supplementation had no effect on baseline blood glucose or insulin levels. ABA supple-
mentation has been shown to increase glucose-potentiated insulin release and has been proposed as an adjunc-
tive treatment for type-2 diabetes28,29. Because hypoglycemia and hyperinsulinemia are pathological symptoms 
associated with malaria30, we sought to explore the potential for ABA to exacerbate these conditions. Neither 
baseline glucose nor insulin levels, however, were significantly different from controls after two weeks of oral ABA 
supplementation in uninfected or P. yoelii 17XNL-infected C57BL/6 mice (day 11 PI, Fig. 5B,C).
Figure 4. Oral ABA supplementation increased circulating levels of ABA in mouse plasma. ABA 
concentrations, measured by LC-MS/MS, in plasma of uninfected and P. yoelii 17XNL-infected wild type 
C57BL/6 (WT) and caspase-1 knockout (casp1−/−) mice with and without ABA supplementation. Plasma 
samples were collected on day 11 PI. Each dot represents one mouse sacrificed from those represented in Fig. 2. 
Data were analyzed by unpaired t-test.
Figure 5. ABA supplementation rescued blood urea nitrogen levels in P. yoelii 17XNL-infected mice but 
did not alter glucose or insulin levels in plasma. Blood urea nitrogen (A) glucose (B), and insulin levels 
(C) in plasma of uninfected mice and P. yoelii 17XNL-infected mice (day 11 PI) with and without ABA 
supplementation. Each dot represents one mouse sacrificed from those represented in Fig. 2. Data were 
analyzed by unpaired t-test.
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ABA increased the proportion of eosinophils and basophils in blood of P. yoelii 17XNL-infected 
C57BL/6 mice. Complete blood counts (CBC, University of California Davis Comparative Pathology Lab) 
were performed on whole blood from uninfected and P. yoelii 17XNL-infected mice (day 11 PI) with and without 
ABA supplementation. In the absence of infection, ABA had no effect on blood cell composition (percentages of 
neutrophils, lymphocytes, monocytes, eosinophils, basophils, and platelets), hemoglobin levels, or percent hema-
tocrit (Supplementary Table S2). In the presence of infection, the percentages of eosinophils and basophils were 
reduced and ABA significantly increased these to levels approaching those in uninfected mice (Fig. 6). Though 
little is known about the role that eosinophils and basophils play in malaria, eosinophilia has been associated 
with recovery from infection31,32. No other changes in blood cells or hemoglobin values were observed with ABA 
supplementation (Supplementary Table S2).
Gene expression patterns associated with ABA supplementation were suggestive of inflam-
masome activation and antibody isotype switching in P. yoelii 17XNL-infected mice. We mon-
itored spleen and liver gene expression from days 9–13 PI in C57BL/6 mice, the period corresponding to the 
greatest reductions in parasitemia following ABA supplementation (Fig. 2, Supplementary Fig. 2). We compared 
gene expression in these tissues to that in the same tissues in CD-1 mice at days 4–7 PI, reflecting our previous 
observations that the effects of ABA on parasitemia occurred earlier in this mouse strain22. In spleen of C57BL/6 
mice, expression levels of ifnγ, nos2, il6, and tbet were decreased in ABA-supplemented mice at day 10 PI. A 
trend towards decreased tbet was also evident at day 13 PI (Fig. 7A). No change in tnfα expression was evident at 
any timepoint. These patterns were consistent with those in spleen of CD-1 mice at days 4–7 PI (Supplementary 
Fig. S3A)22.
In livers of C57BL/6 mice, a significant increase in pparγ expression was evident by day 13 PI (Fig. 8A). Il18 
expression was significantly lower in ABA-treated mice on day 9 but increased compared to controls on days 
11 and 13 PI. Il1β mRNA levels did not change significantly at any timepoint while il6 expression increased 
on day 10 PI (Fig. 8A). Increased expression of il18 has been associated with inflammasome activation33,34 and 
contributes to parasite killing in the liver35. IL-6 can function in concert with IL-1β to induce the synthesis of 
specific acute phase proteins36. However, IL-6 can also signal through an alternate pathway to promote regener-
ative and anti-inflammatory signaling in the liver37–39, effects that would be consistent with reduced parasitemia 
in ABA-treated mice as well as reduced hepatomegaly at day 9 PI (Fig. 3A) and recovery of BUN in ABA-treated, 
infected mice to control levels at day 11 PI (Fig. 5A). ABA-induced gene expression in the liver was similar to 
patterns in CD-1 mice (Supplementary Fig. S3B)22, although increases in il6 and il1β in the liver were more pro-
nounced in ABA-treated, infected CD-1 mice (Supplementary Fig. S3B). Collectively, the consistency of effects 
of ABA on parasitemia, hepatosplenomegaly, and gene expression patterns in spleen and liver of ABA-treated, 
infected C57BL/6 and CD-1 mice suggested that ABA effects were robust across divergent mouse models and 
provided good confidence for testing hypotheses in the more tractable inbred strain.
ABA supplementation increased levels of parasite-specific, protective circulating IgG antibod-
ies in P. yoelii 17XNL-infected C57BL/6 mice. Based on gene expression patterns in the spleen (Fig. 7A, 
Supplementary Fig. S3A), we hypothesized that ABA supplementation could alter antibody synthesis and perhaps 
isotype patterns in infected mice. Specifically, reduced tbet expression in B cells can increase total IgG synthesis 
while increased tbet expression correlates with reduced IgG1 production40,41. Additionally, low levels of IFNγ 
can enhance IgG1 synthesis42, suggesting that ABA-induced repression of tbet and ifnγ in the spleen at day 10 PI 
(Fig. 7A) could increase total IgG and IgG1 in P. yoelii 17XNL-infected mice.
To determine whether these patterns were evident in our model, we measured antibody levels in plasma from 
control and ABA-supplemented P. yoelii 17XNL-infected C57BL/6 mice on days 9, 11, and 13 PI. Levels of IgG1 
and IgG2c in ABA-supplemented mice were significantly greater than control levels by day 13 PI, with no changes 
noted in other isotypes (Fig. 9). Parasitemia and antibody titers were significantly negatively correlated, with 
lower parasitemias and higher levels of IgG1 and IgG2c in ABA-supplemented mice (Fig. 10).
Figure 6. ABA supplementation partially rescued the decrease in eosinophils and basophils associated with 
P. yoelii 17XNL infection. Percentage of eosinophils (A) and basophils (B) in whole blood of uninfected mice 
and P. yoelii 17XNL-infected mice (day 11 PI) with and without ABA supplementation. Each dot represents one 
mouse sacrificed from those represented in Fig. 2. Data were analyzed by unpaired t-test.
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To determine whether increased circulating total IgG and the protective isotype IgG1, which was elevated to a 
greater degree than protective IgG2c43 (Fig. 9), were parasite-specific, we examined the cross-reactivity of plasma 
from infected mice (day 13 PI) and from uninfected mice against proteins from P. yoelii 17XNL-infected and 
uninfected RBCs. Plasma from ABA-supplemented, infected mice contained higher levels of parasite-specific 
IgG1 and total IgG compared to unsupplemented, infected mice (Fig. 11A, Supplementary Fig. S4). Specifically, 
densitometry analysis revealed a 1.67-fold increase in levels of cross-reacting IgG1 and a 1.34-fold increase in lev-
els of cross-reacting total IgG in plasma from ABA-supplemented, infected mice compared to unsupplemented, 
infected mice (Fig. 11B). Additionally, IgG1 from ABA-treated mice cross-reacted with at least one unique pro-
tein (~90 kDa) from infected RBCs that was not bound by IgG1 from unsupplemented, infected mice.
To test whether enhance IgG levels were protective, mice were injected (tail vein) with 50 µl of plasma 
pooled from unsupplemented or ABA-supplemented, infected mice. Pooled plasma from ABA-supplemented 
mice used for passive immunization had 1.5-fold higher levels of IgG1 than that from control mice (Fig. 12A). 
At 24 hours after plasma injection, mice were infected with P. yoelii 17XNL. Mice that received plasma from 
ABA-supplemented, infected mice trended towards lower parasitemia and were significantly different than 
control-plasma injected mice on days 6 and 8 PI, suggesting that the plasma provided limited protection against 
infection (Fig. 12B), the duration of which was consistent with the half-life of IgG1 (6–8 days) in serum44.
The effects of ABA on P. yoelii 17XNL parasitemia were ablated in caspase-1-deficient 
mice and this pattern was associated with changes in splenic and hepatic gene expression. 
Inflammasome activation in malaria results in the activation of caspase-1, which cleaves pro-IL-1β and 
IL-18 into their active forms45. To determine whether the effects of ABA on P. yoelii 17XNL infection were 
caspase-1-dependent, we examined parasitemia over time and hepatic and splenic gene expression on day 10 PI, 
when a majority of target mRNA levels were significantly different in ABA-supplemented and unsupplemented 
C57BL/6 mice (Figs 7A, 8A). In age-matched C57BL/6 mice, ABA supplementation significantly reduced para-
sitemia on days 8 and 10 PI (Fig. 13). However, while plasma levels of ABA in wild type and casp1−/− mice were 
comparable (Fig. 4), ABA had no effect on parasitemia in casp1−/− mice from days 7–10 PI (Fig. 13). Intriguingly, 
Figure 7. Splenic gene expression patterns following ABA supplementation were suggestive of enhanced IgG 
production. Relative target gene mRNA levels in spleens of unsupplemented and ABA-supplemented C57BL/6 
mice on days 9, 10, 11, and 13 PI (A) and in casp1−/− mice on day 10 PI with P. yoelii 17XNL (B). Each dot 
represents one mouse with time points in panel (A) collated from three separate cohorts of mice and in panel 
(B) from one cohort of mice. Data are shown as −Δct, normalized to β-actin, and were analyzed by unpaired 
t-test. *p < 0.05, #p < 0.1.
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ABA supplemented wild type mice had significantly lower parasitemias than ABA-supplemented casp1−/− mice 
on days 8 and 10 PI, while parasitemias of unsupplemented wild type and casp1−/− mice did not significantly 
differ (Fig. 13). In the spleen, ABA-dependent decreases in nos2, il6, and tbet expression were ablated in casp1−/− 
mice, while in casp1−/− mice the ABA-dependent decrease in ifnγ was reversed and ABA treatment increased 
pparγ expression (Fig. 7B). In the liver, the ABA-dependent increase in il6 was ablated in casp1−/− mice and il1β 
was significantly reduced in ABA-treated casp1−/− mice (Fig. 8B).
Discussion
In our mouse malaria model, ABA supplementation has minimal to no effects in the absence of malaria and 
improves host health in the presence of parasite infection. In the absence of supplementation, infected mice do 
not generate detectable levels of plasma ABA (Fig. 4)22, so supplementation is necessary to study the effects of 
ABA on infection and pathology. Children with malaria, however, have plasma ABA levels consistent with those 
in supplemented outbred mice22 and elevated ABA levels were significantly associated with reduced risk of symp-
tomatic malaria in the setting of P. falciparum infection. Given this clinical association, we sought to examine the 
mechanisms of ABA action in the context of malaria using a supplemented, genetically tractable mouse model.
We infer that no change or, at most, modest beneficial changes in CBC and plasma enzymes in supplemented 
mice are consistent with the hypothesis that ABA enhances anti-malarial immunity while mitigating inflamma-
tory pathology. In particular, baseline glucose and insulin levels were not altered by ABA supplementation in 
either infected or uninfected mice, despite the fact that ABA can enhance insulin secretion in vitro and can reduce 
Figure 8. Hepatic gene expression patterns following ABA supplementation were suggestive of inflammasome 
activation and consistent with reduced hepatomegaly. Relative target gene mRNA levels in livers of 
unsupplemented and ABA-supplemented C57BL/6 mice on days 9, 10, 11, and 13 PI (A) and in casp1−/− mice 
on day 10 PI with P. yoelii 17XNL (B). Each dot represents one mouse with time points collated from the 
cohorts of mice as in Fig. 7. Data are shown as −Δct, normalized to β-actin, and were analyzed by unpaired 
t-test. *p < 0.05, **p < 0.01.
www.nature.com/scientificreports/
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Figure 9. ABA supplementation increased levels of IgG1 and IgG2c in plasma during P. yoelii infection. Data 
are shown as concentrations of IgM and IgG antibody isotypes in plasma from mice with and without ABA 
supplementation on days 9, 11 and 13 PI with P. yoelii 17XNL. Each dot represents one mouse with time points 
collated from the cohorts of mice as in Fig. 7. Data were analyzed by unpaired t-test.
Figure 10. Levels of IgG1 and IgG2c were negatively correlated with parasitemia. IgG1 and IgG2c levels were 
plotted against parasitemia (days 11 and 13 PI from Fig. 9) from P. yoelii 17XNL-infected mice with and without 
ABA supplementation. Each dot represents one mouse. Data were analyzed by linear regression.
Figure 11. ABA supplementation increased levels of parasite-specific IgG1 and total IgG in mouse plasma. 
(A) Western blots of protein from uninfected and P. yoelii 17XNL-infected RBCs probed with plasma from 
uninfected mice, P. yoelii-infected mice or ABA-supplemented P. yoelii-infected mice followed by secondary 
antibodies to IgG1 and total IgG. The 50 kDa band corresponds to the IgG heavy chain. Asterisk indicates 
unique protein (~90 kDa) bound by IgG1 from ABA-treated, infected mice. Samples for IgG and IgG1 detection 
were each run on a single gel. Membranes were cut for incubation with each type of plasma. Total IgG- and 
IgG1-probed blots were exposed together and images were cropped to remove white space and redundant 
protein ladders. (B) Densitometry analysis of IgG1- and total IgG-bound proteins from iRBCs. Data are 
shown as fold change in plasma from ABA-supplemented P. yoelii-infected mice relative to plasma from 
unsupplemented, infected mice.
www.nature.com/scientificreports/
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fasting glucose levels in a mouse model of diabetes6,29. These observations are consistent with the hypothesis that 
ABA supplementation does not exacerbate malaria-associated hypoglycemia and hyperinsulinemia.
Hepatic immunity clearly controls intrahepatic parasites, but the liver also contributes significantly to the 
control of erythrocytic asexual stages. These contributions include phagocytosis of iRBCs and secretion of the 
cytokines IL-6, TNFα, IL-18, and IL-1β46. IL-6 is typically more highly expressed in the liver than spleen47, sug-
gesting that observed ABA-associated patterns in IL-6 expression warrant further study. IL-6 in the liver regulates 
the synthesis of acute phase proteins and contributes to the resolution of inflammation, the balance of which 
is dependent on classic and trans signaling by IL-6. In classic signaling, IL-6 binds a membrane bound IL-6 
receptor (IL-6R), which interacts with the ubiquitous membrane protein gp130 to initiate JAK/STAT signal-
ing and promote cell proliferation48. This signaling pathway is restricted to cells that express the bound IL-6R, 
including hepatocytes37,38. In trans signaling, IL-6 binds a soluble IL-6R, allowing it to bind to gp130 and initiate 
pro-inflammatory processes, most notably the synthesis of acute phase proteins (APP) in the liver. In the context 
of infection, inflammasome-associated IL-1β shifts IL-6-dependent synthesis of APP to those involved in path-
ogen defense, including hepcidin, C-reactive protein, serum amyloid P, and serum amyloid A49. Correlations 
Figure 12. Plasma from ABA-supplemented mice exhibited limited protection against P. yoelii 17XNL 
infection. (A) Fold change in antibody isotype in pooled plasma from ABA-supplemented infected mice relative 
to unsupplemented, infected mice (day 13 PI). (B) Parasitemias of individual mice injected with plasma from 
unsupplemented, infected mice (control) or ABA supplemented, infected mice (ABA) days 5 through 13 PI. 
Data were analyzed by unpaired t-test. n = 3–4 mice per group.
www.nature.com/scientificreports/
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between genetic mutations in il1β and Plasmodium vivax infection suggest that IL-1β is important for controlling 
parasitemia across Plasmodium species50. The ABA-dependent increase in liver il6 was ablated in casp1−/− 
mice and il1β was significantly reduced in ABA-treated casp1−/− mice (Fig. 8B), suggesting that the balance of 
ABA-dependent host immunity and pathology in our model are caspase-1-dependent.
Increased levels of IgG1, IgG2, and IgG3 have been associated with malaria resistance and have been observed 
to be significantly higher in patients with uncomplicated and asymptomatic malaria compared to those with 
complicated malaria51–54. Similarly, T-bet-deficient mice had lower parasitemia, which correlated with increased 
levels of IgG155. In our studies, plasma from ABA-supplemented mice provided limited protection against P. 
yoelii 17XNL infection. In a single tail vein injection, ABA levels in 50 µl plasma would be < 0.5 nM, provid-
ing confidence that the observed effects were due in part to elevated IgG. The half-life of IgG1 in serum is 6–8 
days44, suggesting that a second injection of plasma post-infection could extend protection. IgG1 may enhance 
parasite clearance via antibody-dependent cell-mediated inhibition (ADCI), in which monocytes are activated 
by antibody-opsonized merozoites and release a soluble factor that blocks the division of intra-erythrocytic par-
asites56. Much lower levels of IgG1 are sufficient to trigger ADCI than is necessary for effective direct neutraliza-
tion. Limited protection, however, also suggests that increased parasite-specific IgG is only one component of the 
protective response induced by ABA supplementation.
Caspase-1 deficiency abrogated the effect of ABA on parasitemia, suggesting that caspase-1 mediated immu-
nity is critical to the reduction in parasitemia by ABA. Notably, the effects of ABA supplementation on tbet and 
ifnγ expression, which we hypothesize are driving protective IgG production, were eliminated or reversed in 
casp1−/− mice (Fig. 7B). Caspase-1 also plays a role in IgG production during influenza infection. Specifically, 
caspase-1 knockout mice had reduced total IgG levels compared to wild type mice, but this was due mainly to 
reduced IgG3 levels and reductions in IgG1 levels were not observed57. The lack of effect of ABA supplemen-
tation on parasitemia in casp1−/− mice suggests that inflammasome activation is the primary mechanism by 
which parasitemia is reduced. However, increased IgG may contribute to long-term immunity. Both the reduction 
in pathology and the enhanced IgG production in our model are consistent with the observations that higher 
plasma ABA concentrations were significantly associated with non-febrile falciparum malaria. Antibodies against 
P. falciparum-infected RBCs, as well as higher levels of IgG1, IgG2, and IgG3, have been associated with asymp-
tomatic infection rather than symptomatic, febrile malaria52,58. Future work, however, is needed to determine 
whether ABA-enhanced antibody production provides protection against or enhances tolerance to infection.
Methods
Human plasma collection and ABA quantification. Plasma samples were selected from 122 P. falci-
parum infected children presenting for routine visits in the Nagongera and Kanungu surveillance cohorts of the 
East African International Center of Excellence in Malaria Research (ICEMR). The study protocol was reviewed 
and approved by the Uganda National Council of Science and Technology and the institutional review boards of 
the University of California–San Francisco, and Makerere University (DMID Protocol 10-0063). All experiments 
were performed in accordance with Good Clinical Practice (US Code of Federal Regulations,Ugandan Ethics 
Committee, and NIH/NIAID). Informed consent was obtained from the parent or guardian of all participating 
children. Samples were selected based on age stratification (2–4 and 7–9 year-olds), and log parasite density 
(range: 32 to >100,000 parasites/µL). Parasitemia at routine visits was determined and quantified by microscopy 
of thick blood smears, as previously described23. Symptomatic subjects were defined as those with fever at the 
time of the visit or with a reported history of fever. ABA was extracted from plasma as previously described22 and 
quantified using the Phytodetek Abscisic Acid ELISA kit (Agdia, Elkhart, IN) according to the manufacturer’s 
instructions. ABA levels were analyzed by unpaired t-test.
ABA was quantified in mouse plasma by LC-MS/MS using an AB Sciex API2000 tandem mass spectrometer 
coupled with PE 200 series micro LC pumps (calibration range 25–10,000 ng/mL) or API5000 tandem mass 
spectrometer coupled with Shimadzu Prominence 20ADXR LC pumps (calibration range 0.5–50 ng/mL). ABA 
was extracted from EDTA mouse plasma samples by solid phase extraction with Oasis® HLB micro-elution plate. 
Extracted samples were injected onto a Zorbax C8 LC column and eluted with 10 mM NH4FA-acetonitrile con-
taining 0.1% formic acid. Electrospray ionization in negative mode and multiple reaction monitoring were used, 
and ion pairs m/z 263- >153 was selected for quantification. ABA levels were analyzed by unpaired t-test.
Figure 13. ABA supplementation did not reduce parasitemia in caspase-1 knockout mice. Parasitemias of 
individual wild type (WT) and casp1−/− mice with and without ABA supplementation from days 7 to 10 PI. 4–5 
mice were used per treatment group. Data were analyzed by unpaired t-test.
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ABA supplementation and infection. Mice received control or 2.56 mM ABA-supplemented water 
three days prior to intraperitoneal (IP) injection with 1 × 107 P. yoelii 17XNL-iRBCs as described previously22. 
Parasitemias were determined from thin blood films stained with Giemsa and were defined as the percentage 
of iRBCs divided by total RBCs. Mice were sacrificed on days 9, 10, 11 and 13 PI. Parasitemia was analyzed 
by unpaired t-test. Hepatic and splenic gene expression data were obtained from CD-1 mice with previously 
quantified parasitemias22. Casp1−/− mice were obtained from Jackson Labs. Age-matched (6–8 week old) wild 
type C57BL/6 mice (Jackson Labs) were used as controls. All experiments were performed in accordance with 
the recommendations in the Guide for Care and Use of Laboratory Animals of the National Institute of Health 
and were approved by the Institutional Animal Care and Use Committees at the University of California at Davis 
under protocol 18948.
Blood analysis. Blood was collected from individual mice via heart puncture with heparinized needles on 
day 11 PI. Whole blood was collected in heparinized tubes and CBC performed using a HemaVet 950 FS (Drew 
Scientific). Blood was centrifuged at 5,900 × g for 8 min for plasma collection. Aliquots of plasma were stored at 
−20 °C and insulin levels determined using the Ultra Sensitive Mouse Insulin ELISA Kit (Crystal Chem #90080) 
according to the manufacturer’s instructions. Blood cell counts and analytes were analyzed by unpaired t-test.
qRT-PCR. Harvested liver and spleen were flash frozen and stored at −80 °C. RNA was extracted in TriZOL 
and complementary DNA (cDNA) synthesized according to manufacturer’s instructions (QuantiTect Reverse 
Transcription Kit, Qiagen). Quantitative real time polymerase chain reaction (qRT-PCR) was performed using 
validated TaqMan gene expression assays as previously described for mouse β-actin, nos2, tnfα, ifnγ, pparγ, il6, 
il18, il1β, and tbet (Applied Biosystems)59. Samples were analyzed in triplicate using 250 ng cDNA per reaction. 
Data were normalized to β-actin and analyzed by unpaired t-test. Outliers were tested by ROUT with Q = 2%.
Antibodies and plasma injection. Antibody levels in mouse plasma were determined using the 
ProcartaPlex Mouse Antibody Isotyping Panel (Affymetrix eBioscience EPX070-20815-901) according to the 
manufacturer’s instructions. Day 13 PI plasma from individual mice was pooled. C57BL/6 mice received 50 µL of 
plasma from control or ABA-supplemented infected mice by tail-vein injection. At 24 hours after plasma injec-
tion, mice were infected IP with 1 × 107 P. yoelii 17XNL-infected RBCs.
Western blot. Blood was collected from uninfected and P. yoelii 17XNL-infected mice and centrifuged at 
2,000 × g for 10 min at room temperature to isolate RBCs. Equivalent volumes of collected RBCs were washed 
twice with RPMI medium before being suspended in lysis buffer. RBC proteins were separated by gel by electro-
phoresis, transferred to nitrocellulose, and incubated overnight at 4 °C in 5% dry milk in Tris-buffered saline, 
0.1% Tween 20 (TBST). Gels were stained with Coomassie to quantify total protein. Membranes were incubated 
for 2 hours at room temperature with 1:100 dilutions of plasma from uninfected mice, from infected mice at day 
13 PI, or from ABA-treated infected mice at day 13 PI. Washed membranes were then incubated with 1:1000 goat 
anti-mouse IgG1 (Abcam #ab97240) or 1:1000 rabbit anti-mouse IgG (Sigma #A9044) HRP-conjugated second-
ary antibodies for 1 hour at room temperature.
Data availability. All data generated or analyzed during this study are included in this published article and 
its Supplementary Information files.
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